

ATTORNEY DOCKET NO.: 056291-5046


Application No.: 09/937,018

Page 2

**IN THE CLAIMS:**

Claim 1 (canceled).

Claim 2 (currently amended and reformatted): A **bicyclic** ~~bicyclic~~ compound of the Formula (I); ~~according to claim 1~~



wherein:

**G is N;**

the bicyclic ring formed by the fusion of ring X to the adjacent nitrogen-containing 6-membered heteroaryl ring within Formula (I) is furopyrimidinyl, thienopyrimidinyl, pyrrolopyrimidinyl, oxazolopyrimidinyl, thiazolopyrimidinyl, purinyl, pyridopyrimidinyl, pyrimidopyrimidinyl or pteridinyl;

**m is 0 or m is 1; and each**

**R¹ is independently** hydroxy, halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkylS(O)<sub>n</sub> (wherein n is 0-2), N,N-(C<sub>1-6</sub>alkyl)<sub>2</sub>aminoC<sub>1-6</sub>alkyl, N,N-(C<sub>1-6</sub>alkyl)<sub>2</sub>carbonylC<sub>1-6</sub>alkoxy, N,N-(C<sub>1-6</sub>alkyl)<sub>2</sub>aminoC<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkylS(O)<sub>2</sub>-C<sub>1-6</sub>alkoxy, N,N-(C<sub>1-6</sub>alkyl)<sub>2</sub>amino-N-(C<sub>1-6</sub>alkyl)C<sub>1-6</sub>alkylamino, N,N-(C<sub>1-6</sub>alkyl)<sub>2</sub>aminoC<sub>1-6</sub>alkylaminoC<sub>1-6</sub>alkyl, piperidin-1-ylC<sub>1-6</sub>alkyl, homopiperidin-1-ylC<sub>1-6</sub>alkyl, N-(C<sub>1-6</sub>alkyl)piperidin-1-ylC<sub>1-6</sub>alkyl, N-(C<sub>1-6</sub>alkyl) homopiperidin-1-ylC<sub>1-6</sub>alkyl, piperazin-1-ylC<sub>1-6</sub>alkyl, 4-C<sub>1-6</sub>alkylpiperazin-1-ylC<sub>1-6</sub>alkyl, homopiperazinyl-1-ylC<sub>1-6</sub>alkyl, 4-C<sub>1-6</sub>alkylhomopiperazinyl-1-ylC<sub>1-6</sub>alkyl, pyrrolidinylC<sub>1-6</sub>alkoxy, piperidinylC<sub>1-6</sub>alkoxy, homopiperidinylC<sub>1-6</sub>alkoxy, N-(C<sub>1-6</sub>alkyl)pyrrolidinylC<sub>1-6</sub>alkoxy, N-(C<sub>1-6</sub>alkyl)piperidinylC<sub>1-6</sub>alkoxy,

ATTORNEY DOCKET NO.: 056291-5046

Application No.: 09/937,018

Page 3

*N*-(C<sub>1-6</sub>alkyl)homopiperidinylC<sub>1-6</sub>alkoxy, morpholinylC<sub>1-6</sub>alkoxy, piperazinylC<sub>1-6</sub>alkoxy, *N*-(C<sub>1-6</sub>alkyl)piperazinylC<sub>1-6</sub>alkoxy, homopiperazinylC<sub>1-6</sub>alkoxy, *N*-(C<sub>1-6</sub>alkyl)homopiperazinylC<sub>1-6</sub>alkoxy, pyrrolidinylC<sub>1-6</sub>alkoxy, *N*-(C<sub>1-6</sub>alkyl)pyrrolidinylC<sub>1-6</sub>alkoxy, piperidinylC<sub>1-6</sub>alkoxy, *N*-(C<sub>1-6</sub>alkyl)piperidinylC<sub>1-6</sub>alkoxy, homopiperidinylC<sub>1-6</sub>alkoxy, *N*-(C<sub>1-6</sub>alkyl)homopiperidinylC<sub>1-6</sub>alkoxy, morpholinylC<sub>1-6</sub>alkylaminoC<sub>1-6</sub>alkyl, thiazolylC<sub>1-6</sub>alkoxy or pyridylC<sub>1-6</sub>alkoxy;

and any aryl, heteroaryl or heterocyclyl group in a R<sup>1</sup> group may be optionally substituted with one or more groups selected from hydroxy, halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, carboxy, C<sub>1-6</sub>alkoxycarbonyl, carbamoyl, *N*-C<sub>1-6</sub>alkylcarbamoyl, *N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>carbamoyl, C<sub>2-6</sub>alkanoyl, amino, *N*-C<sub>1-6</sub>alkylamino and *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>amino, and any heterocyclyl group in a R<sup>1</sup> group may be optionally substituted with one or two oxo or thioxo substituents,

and any of the R<sup>1</sup> groups defined hereinbefore which comprises a CH<sub>2</sub> group which is attached to 2 carbon atoms or a CH<sub>3</sub> group which is attached to a carbon atom may optionally bear on each said CH<sub>2</sub> or CH<sub>3</sub> group a substituent selected from hydroxy, amino, C<sub>1-6</sub>alkoxy, *N*-C<sub>1-6</sub>alkylamino, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>amino and heterocyclyl;

R<sup>2</sup> is hydrogen, C<sub>1-4</sub>alkyl or halo;

R<sup>3</sup> is hydrogen, C<sub>1-4</sub>alkyl or halo;

q is 0;

R<sup>4</sup> is phenyl, thienyl, furyl, oxazolyl, isoxazolyl, pyrimidyl or pyridyl optionally substituted by one or two halo, trifluoromethyl, cyano, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, -O-(C<sub>1-3</sub>alkyl)-O-, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>amino, C<sub>1-6</sub>alkanoylamino, C<sub>1-6</sub>alkylsulphonyl-*N*-(C<sub>1-6</sub>alkyl)amino, phenyl (optionally substituted by one or two halo groups), furyl, azetidyl, pyrrolidinyl, 3-pyrrolinyl, piperidinyl ~~piperidino~~, homopiperidinyl, morpholino, piperazinyl, homopiperazinyl, *N*-(C<sub>1-6</sub>alkyl)piperazinyl and *N*-(C<sub>1-6</sub>alkyl)homopiperazinyl, or R<sup>4</sup> is fluorenyl or dibenzofuranyl;

and any aryl, heteroaryl or heterocyclyl group in a R<sup>4</sup> group may be optionally substituted by one or more groups selected from hydroxy, halo, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, carbamoyl, formyl, sulphamoyl, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, C<sub>1-6</sub>alkoxy, -O-(C<sub>1-3</sub>alkyl)-O-, C<sub>1-6</sub>alkylS(O)<sub>n</sub>- (wherein n is 0-2), *N*-C<sub>1-6</sub>alkylamino,


ATTORNEY DOCKET NO.: 056291-5046

Application No.: 09/937,018

Page 4

*N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>amino, C<sub>1-6</sub>alkoxycarbonyl, *N*-C<sub>1-6</sub>alkylcarbamoyl, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>carbamoyl, C<sub>2-6</sub>alkanoyl, C<sub>1-6</sub>alkanoyloxy, C<sub>1-6</sub>alkanoylamino, *N*-C<sub>1-6</sub>alkylsulphamoyl, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>sulphamoyl, C<sub>1-6</sub>alkylsulphonylamino and C<sub>1-6</sub>alkylsulphonyl-*N*-(C<sub>1-6</sub>alkyl)amino,

or any aryl, heteroaryl or heterocyclyl group in a R<sup>4</sup> group may be optionally substituted with one or more groups of the Formula (IA'):



wherein A<sup>1</sup> is halo, hydroxy, C<sub>1-6</sub>alkoxy, cyano, amino, *N*-C<sub>1-6</sub>alkylamino, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>amino, carboxy, C<sub>1-6</sub>alkoxycarbonyl, carbamoyl, *N*-C<sub>1-6</sub>alkylcarbamoyl or *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>carbamoyl, p is 1 - 6, and B<sup>1</sup> is a bond, oxy, imino, *N*-(C<sub>1-6</sub>alkyl)imino or -NHC(O)-, with the proviso that p is 2 or more unless B<sup>1</sup> is a bond or -NHC(O)-, or any aryl, heteroaryl or heterocyclyl group in a R<sup>4</sup> group may be optionally substituted with one or more groups of the Formula (IB'):



wherein D<sup>1</sup> is aryl, heteroaryl or heterocyclyl and E<sup>1</sup> is a bond, C<sub>1-6</sub>alkylene, oxyC<sub>1-6</sub>alkylene, oxy, imino, *N*-(C<sub>1-6</sub>alkyl)imino, iminoC<sub>1-6</sub>alkylene, *N*-(C<sub>1-6</sub>alkyl)-iminoC<sub>1-6</sub>alkylene, C<sub>1-6</sub>alkylene-oxyC<sub>1-6</sub>alkylene, C<sub>1-6</sub>alkylene-iminoC<sub>1-6</sub>alkylene, C<sub>1-6</sub>alkylene-*N*-(C<sub>1-6</sub>alkyl)-iminoC<sub>1-6</sub>alkylene, -NHC(O)-, -NH<sub>2</sub>SO<sub>2</sub>-, -SO<sub>2</sub>NH- or -NHC(O)-C<sub>1-6</sub>alkylene-, and any aryl, heteroaryl or heterocyclyl group in a substituent on R<sup>4</sup> may be optionally substituted with one or more groups selected from hydroxy, halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, carboxy, C<sub>1-6</sub>alkoxycarbonyl, carbamoyl, *N*-C<sub>1-6</sub>alkylcarbamoyl, *N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>carbamoyl, C<sub>2-6</sub>alkanoyl, amino, *N*-C<sub>1-6</sub>alkylamino and *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>amino, and any C<sub>3-7</sub>cycloalkyl or heterocyclyl group in a R<sup>4</sup> group may be optionally substituted with one or two oxo or thioxo substituents, and any of the R<sup>4</sup> groups defined hereinbefore which comprises a CH<sub>2</sub> group which is attached to 2 carbon atoms or a CH<sub>3</sub> group which is attached to a carbon atom may optionally bear on each said CH<sub>2</sub> or CH<sub>3</sub> group a substituent selected from hydroxy, amino, C<sub>1-6</sub>alkoxy, *N*-C<sub>1-6</sub>alkylamino, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>amino and heterocyclyl;

ATTORNEY DOCKET NO. : 056291-5046

Application No.: 09/937,018

Page 5

and

 $R^5$  is hydrogen;or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof.

Claim 3 (currently amended): A bicyclic compound of the Formula (I) according to claim 2 wherein:

~~the bicyclic ring formed by the fusion of ring X to the adjacent nitrogen-containing 6-membered heteroaryl ring within Formula (I) is furopyrimidinyl, thienopyrimidinyl, pyrrolopyrimidinyl, oxazolopyrimidinyl, thiazolopyrimidinyl, purinyl, pyridopyrimidinyl, pyrimidopyrimidinyl or pteridinyl;~~

~~m is 0 or m is 1 and each  $R^1$  is independently hydroxy, halo,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy,~~

~~$C_{1-6}$ alkylS(O)<sub>n</sub>- (wherein n is 0-2),  $N,N$ -( $C_{1-6}$ alkyl)<sub>2</sub>amino $C_{1-6}$ alkyl,~~

~~$N,N$ -( $C_{1-6}$ alkyl)<sub>2</sub>carbamoyl $C_{1-6}$ alkoxy,  $N,N$ -( $C_{1-6}$ alkyl)<sub>2</sub>amino $C_{1-6}$ alkoxy,~~

~~$C_{1-6}$ alkylS(O)<sub>2</sub>- $C_{1-6}$ alkoxy,  $N,N$ -( $C_{1-6}$ alkyl)<sub>2</sub>amino- $N$ -( $C_{1-6}$ alkyl) $C_{1-6}$ alkylamino,~~

~~$N,N$ -( $C_{1-6}$ alkyl)<sub>2</sub>amino $C_{1-6}$ alkylamino $C_{1-6}$ alkyl, piperazin-1-yl $C_{1-6}$ alkyl, 4- $C_{1-6}$ alkylpiperazin-~~

~~1-yl $C_{1-6}$ alkyl, homopiperazinyl-1-yl $C_{1-6}$ alkyl, 4- $C_{1-6}$ alkylhomopiperazinyl-1-yl $C_{1-6}$ alkyl,~~

~~pyrrolidinyl $C_{1-6}$ alkoxy, piperidinyl $C_{1-6}$ alkoxy,  $N$ -( $C_{1-6}$ alkyl)pyrrolidinyl $C_{1-6}$ alkoxy,~~

~~$N$ -( $C_{1-6}$ alkyl)piperidinyl $C_{1-6}$ alkoxy, morpholinyl $C_{1-6}$ alkoxy, piperazinyl $C_{1-6}$ alkoxy,~~

~~$N$ -( $C_{1-6}$ alkyl)piperazinyl $C_{1-6}$ alkoxy, homopiperazinyl $C_{1-6}$ alkoxy,~~

~~$N$ -( $C_{1-6}$ alkyl)homopiperazinyl $C_{1-6}$ alkoxy, pyrrolidinyl $C_{1-6}$ alkoxy, piperidinyl $C_{1-6}$ alkoxy,~~

~~morpholinyl $C_{1-6}$ alkylamino $C_{1-6}$ alkyl or pyridyl $C_{1-6}$ alkoxy; and~~

~~$R^2$  is hydrogen,  $C_{1-4}$ alkyl or halo;~~

~~$R^3$  is hydrogen,  $C_{1-4}$ alkyl or halo;~~

~~q is 0;~~

~~$R^4$  is phenyl, thienyl, furyl, oxazolyl, isoxazolyl, pyrimidyl or pyridyl optionally substituted by~~

~~one or two halo, cyano,  $C_{1-4}$ alkyl,  $C_{1-4}$ alkoxy,  $N,N$ -( $C_{1-4}$ alkyl)<sub>2</sub>amino, piperidinyl, morpholino~~

~~or piperazinyl; and~~

~~$R^5$  is hydrogen;~~

or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof.

ATTORNEY DOCKET NO.: 056291-5046

Application No.: 09/937,018

Page 6

Claim 4 (currently amended): A bicyclic compound of the Formula (I) according to claim 2 ~~1~~ wherein:

the bicyclic ring formed by the fusion of ring X to the adjacent nitrogen-containing

6-membered heteroaryl ring within Formula (I) is furo[3,2-*d*]pyrimidinyl, furo[2,3-*d*]pyrimidinyl, thieno[3,2-*d*]pyrimidinyl, thieno[2,3-*d*]pyrimidinyl, pyrrolo[3,2-*d*]pyrimidinyl, pyrrolo[2,3-*d*]pyrimidinyl, oxazolo[5,4-*d*]pyrimidinyl, oxazolo[4,5-*d*]pyrimidinyl, thiazolo[5,4-*d*]pyrimidinyl, thiazolo[4,5-*d*]pyrimidinyl, purinyl, pyrido[2,3-*d*]pyrimidinyl, pyrido[3,4-*d*]pyrimidinyl, pyrido[4,3-*d*]pyrimidinyl, pyrido[3,2-*d*]pyrimidinyl, pyrimido[4,5-*d*]pyrimidinyl, pyrimido[5,6-*d*]pyrimidinyl or pteridinyl;

~~m is 0 or m is 1 and each~~ R<sup>1</sup> is ~~independently~~ methyl, methoxy, methylthio, 2-diisopropylaminoethoxy, 3-diethylaminopropoxy, 3-morpholinopropoxy or 3-pyrrolidin-1-ylpropoxy;

R<sup>2</sup> is hydrogen, methyl, fluoro or chloro;

R<sup>3</sup> is hydrogen; and

~~q is 0;~~

R<sup>4</sup> is phenyl optionally substituted by one or two groups selected from fluoro, chloro, trifluoromethyl, cyano, methyl, methoxy, ethoxy, methylenedioxy, *N,N*-dimethylamino, acetamido, *N*-methylmethanesulphonamido, phenyl, 4-fluorophenyl, 4-chlorophenyl, 2-furyl, azetidin-1-yl, pyrrolidin-1-yl, 3-pyrrolin-1-yl, piperidino, homopiperidin-1-yl, morpholino, piperazin-1-yl, homopiperazin-1-yl, 4-methylpiperazin-1-yl and 4-methylhomopiperazin-1-yl,

or R<sup>4</sup> is pyridyl optionally substituted by a *N,N*-dimethylamino, *N,N*-diethylamino, azetidin-1-yl, pyrrolidin-1-yl, 3-pyrrolin-1-yl, piperidino, homopiperidin-1-yl, morpholino, piperazin-1-yl, homopiperazin-1-yl, 4-methylpiperazin-1-yl or 4-methylhomopiperazin-1-yl group, or R<sup>4</sup> is 1-fluorenyl or dibenzofuran-4-yl; ~~and~~

~~R<sup>5</sup> is hydrogen;~~

or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof.

ATTORNEY DOCKET NO.: 056291-5046

Application No.: 09/937,018

Page 7

Claim 5 (currently amended): A bicyclic compound of the Formula (I) according to claim ~~2~~ **1** wherein:

the bicyclic ring formed by the fusion of ring X to the adjacent nitrogen-containing

6-membered heteroaryl ring within Formula (I) is furo[3,2-*d*]pyrimidinyl, furo[2,3-*d*]pyrimidinyl, thieno[3,2-*d*]pyrimidinyl, thieno[2,3-*d*]pyrimidinyl, pyrrolo[3,2-*d*]pyrimidinyl, pyrrolo[2,3-*d*]pyrimidinyl, oxazolo[5,4-*d*]pyrimidinyl, oxazolo[4,5-*d*]pyrimidinyl, thiazolo[5,4-*d*]pyrimidinyl, thiazolo[4,5-*d*]pyrimidinyl, purinyl, pyrido[2,3-*d*]pyrimidinyl, pyrido[3,4-*d*]pyrimidinyl, pyrido[4,3-*d*]pyrimidinyl, pyrido[3,2-*d*]pyrimidinyl, pyrimido[4,5-*d*]pyrimidinyl, pyrimido[5,6-*d*]pyrimidinyl or pteridinyl;

~~m is 0 or m is 1 and each R<sup>1</sup> is independently~~ methyl, methoxy, methylthio,

2-diisopropylaminoethoxy, 3-diethylaminopropoxy, 3-morpholinopropoxy or

3-pyrrolidin-1-ylpropoxy;

R<sup>2</sup> is hydrogen, methyl, fluoro or chloro;

R<sup>3</sup> is hydrogen; and

~~q is 0;~~

R<sup>4</sup> is pyridyl optionally substituted by a *N,N*-dimethylamino, *N,N*-diethylamino, pyrrolidin-1-yl, piperidino or morpholino group; and

~~R<sup>5</sup> is hydrogen;~~

or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof.

Claim 6 (currently amended): A bicyclic compound of the Formula (I) according to claim ~~2~~ **Claim 1** wherein:

the bicyclic ring formed by the fusion of ring X to the adjacent nitrogen-containing

6-membered heteroaryl ring within Formula (I) is thieno[3,2-*d*]pyrimidin-4-yl, thieno[2,3-*d*]pyrimidin-4-yl, thiazolo[5,4-*d*]pyrimidin-7-yl, 6-purinyl, pyrido[2,3-*d*]pyrimidin-4-yl, pyrido[3,4-*d*]pyrimidin-4-yl, pyrido[4,3-*d*]pyrimidin-4-yl, pyrido[3,2-*d*]pyrimidin-4-yl or pteridin-4-yl;

~~m is 0 or m is 1 and R<sup>1</sup> is~~ methyl or methylthio;

R<sup>2</sup> is methyl;

ATTORNEY DOCKET NO.: 056291-5046

Application No.: 09/937,018

Page 8

$R^3$  is hydrogen; and

~~q is 0;~~

$R^4$  is phenyl, 3-fluorophenyl, 4-cyanophenyl, 2-methylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 3-ethoxyphenyl, 3,4-dimethoxyphenyl, 3,4-methylenedioxyphenyl, 3-(*N,N*-dimethylamino)phenyl, 3-acetamidophenyl, 3-(4-fluorophenyl)phenyl, 3-(2-furyl)phenyl, 3-pyrrolidin-1-ylphenyl, 3-morpholinophenyl, 3-fluoro-5-pyrrolidin-1-ylphenyl, 3-fluoro-5-piperidinophenyl, 3-fluoro-5-morpholinophenyl or 3-morpholino-5-trifluoromethylphenyl, or  $R^4$  is 2-morpholinopyrid-4-yl, or  $R^4$  is 1-fluorenyl or dibenzofuran-4-yl; and

~~$R^5$  is hydrogen;~~

or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof.

Claim 7 (currently amended): A bicyclic compound of the Formula (I) according to claim 2 ~~1~~ wherein:

the bicyclic ring formed by the fusion of ring X to the adjacent nitrogen-containing

6-membered heteroaryl ring within Formula (I) is thieno[3,2-*d*]pyrimidin-4-yl,

thieno[2,3-*d*]pyrimidin-4-yl, thiazolo[5,4-*d*]pyrimidin-7-yl, pyrido[2,3-*d*]pyrimidin-4-yl,

pyrido[3,4-*d*]pyrimidin-4-yl, pyrido[4,3-*d*]pyrimidin-4-yl, pyrido[3,2-*d*]pyrimidin-4-yl or

pteridin-4-yl;

~~m is 0 or m is 1 and~~  $R^1$  is methyl or methylthio;

$R^2$  is methyl;

$R^3$  is hydrogen; and

~~q is 0;~~

$R^4$  is 2-morpholinopyrid-4-yl; and

~~$R^5$  is hydrogen;~~

or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof.

Claim 8 (currently amended): A bicyclic compound of the Formula (I) according to claim 2 ~~1~~ selected from:

4-[2-methyl-5-(2-morpholinopyridine-4-carboxamido)anilino]thieno[3,2-*d*]pyrimidine,

ATTORNEY DOCKET NO.: 056291-5046


Application No.: 09/937,018

Page 9


4-[2-methyl-5-(2-morpholinopyridine-4-carboxamido)anilino]pyrido[4,3-*d*]pyrimidine,  
 4-[2-methyl-5-(2-morpholinopyridine-4-carboxamido)anilino]pteridine and  
 6-[2-methyl-5-(2-morpholinopyridine-4-carboxamido)anilino]purine;  
 or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof.

Claim 9 (currently amended): A process for preparing a compound of the Formula (I), or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof, according to claim 21 which comprises:

a) reacting an aniline of the Formula (II):




with an acyl compound of the Formula (III):



wherein G, R¹, R², R³, R⁴, R⁵, m, q and the bicyclic ring formed by the fusion of ring X to the adjacent nitrogen-containing 6-membered heteroaryl ring ring x, m and q are as defined in claim 21 and L is a displaceable group;

b) reacting an activated bicyclic heteroaryl ring of the Formula (IV):






ATTORNEY DOCKET NO.: 056291-5046

Application No.: 09/937,018

Page 10

wherein G, R<sup>1</sup>, ~~ring X and m~~ and the bicyclic ring formed by the fusion of ring X to the adjacent nitrogen-containing 6-membered heteroaryl ring are as defined in claim 2 ~~1~~ and wherein L is a displaceable group, with an aniline of the Formula (V):



wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and q are as defined in claim 2 ~~1~~; or

- c) for the preparation of a compound of the Formula (I) wherein R<sup>1</sup> or a substituent on R<sup>4</sup> is C<sub>1-6</sub>alkoxy or substituted C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkylS-, N-C<sub>1-6</sub>alkylamino, N,N-(C<sub>1-6</sub>alkyl)<sub>2</sub>amino ~~or substituted C<sub>1-6</sub>alkylamino~~, the alkylation, conveniently in the presence of a suitable base, of a compound of the Formula (I) wherein R<sup>1</sup> or a substituent on R<sup>4</sup> is hydroxy, mercapto or amino as appropriate;

and thereafter if necessary:

- i) converting a compound of the Formula (I) into another compound of the Formula (I);
- ii) removing any protecting groups; and
- iii) forming a pharmaceutically acceptable salt or *in vivo* cleavable ester.

Claim 10. (currently amended): A pharmaceutical composition which comprises a bicyclic compound of the Formula (I), or a pharmaceutically acceptable salt or *in vivo* cleavable ester thereof, according to any one of claims 2-8 ~~1-8~~ in association with a pharmaceutically acceptable diluent or carrier.

Claim 11 (canceled).

Claim 12 (currently amended): A method of treating a disease or medical condition mediated by cytokines which comprises administering to a warm-blooded animal in need thereof an effective amount of a bicyclic compound of the Formula (I), or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof, according to any one of claims 2-8 ~~1-8~~.

ATTORNEY DOCKET NO. : 056291-5046

Application No.: 09/937,018

Page 11

Claim 13 (canceled).

Claim 14 (new): A method for producing an enzyme p38 kinase inhibiting effect in a warm-blooded animal which comprises administering to said animal an enzyme inhibiting amount of a compound of Formula (I), or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof, according to any one of claims 2-8.

Claim 15 (new): A method for producing a TNF $\alpha$  inhibiting effect in a warm-blooded animal which comprises administering to said animal a TNF $\alpha$  inhibiting amount of a compound of Formula (I), or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof, according to any one of claims 2-8.

Claim 16 (new): A method for the treatment of rheumatoid arthritis in a warm-blooded animal in need thereof comprising administering to said animal a treatment-effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof, according to any one of claims 2-8.